CDA | Evidence Driven
CDA | Evidence Driven

Yondelis for Liposarcoma or Leiomyoscarcoma – Details

Details

Files
Generic Name:
Trabectedin
Project Status:
Complete
Therapeutic Area:
Metastatic Liposarcoma or Leiomyosarcoma
Manufacturer:
Janssen Inc.
Brand Name:
Yondelis
Project Line:
Reimbursement Review
Project Number:
PC0071-000
NOC Status at Filing:
Post NOC
Performance Metric:
Achieved
Strength:
1mg/vial
Tumour Type:
Sarcoma
Indications:
Metastatic Liposarcoma or Leiomyosarcoma
Funding Request:
For the treatment of patients with metastatic liposarcoma or leiomyosarcoma after failure of prior anthracycline and ifosfamide chemotherapy
Sponsor:
Janssen Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Not Requested
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Do not reimburse
pERC Meeting:
Final Recommendation Issued:

Files

Provincial Funding Summary View PDF
Trabectedin (Yondelis) for Liposarcoma or Leiomyoscarcoma – pERC Final Recommendation Final Recommendation August 5, 2016 View PDF
Trabectedin (Yondelis) for Liposarcoma or Leiomyoscarcoma – Final Clinical Guidance Report Guidance Reports June 3, 2016 View PDF
Trabectedin (Yondelis) for Liposarcoma or Leiomyoscarcoma – Final Economic Guidance Report Guidance Reports June 3, 2016 View PDF
Trabectedin (Yondelis) for Liposarcoma or Leiomyoscarcoma – pERC Initial Recommendation Initial Recommendation June 3, 2016 View PDF
Trabectedin (Yondelis) for Liposarcoma or Leiomyoscarcoma – PAG Feedback on Initial Recommendation Feedback August 5, 2016 View PDF
Trabectedin (Yondelis) for Liposarcoma or Leiomyoscarcoma – Manufacturer Feedback on Initial Recommendation Feedback August 5, 2016 View PDF
Trabectedin (Yondelis) for Liposarcoma or Leiomyoscarcoma – Patient Advocacy Group COI Declarations COI Declarations August 5, 2016 View PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Last Updated : August 22, 2016